Dr. Abou-Alfa on the Ongoing Impact and Role of Regorafenib in HCC

Ghassan K. Abou-Alfa, MD
Published: Wednesday, Nov 08, 2017



Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Regorafenib, Abou-Alfa explains, is a unique agent that should not bee known as a "cousin" to sorafenib (Nexavar). In a study, regorafenib was compared with placebo in patients with HCC who progressed on sorafenib, which showed a 10.7-month improvement in survival.

Patients who progress on standard sorafenib will undoubtedly benefit from treatment with regorafenib, Abou-Alfa explains.

  <<< View more from the 2017 Chemotherapy Foundation Symposium


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Regorafenib, Abou-Alfa explains, is a unique agent that should not bee known as a "cousin" to sorafenib (Nexavar). In a study, regorafenib was compared with placebo in patients with HCC who progressed on sorafenib, which showed a 10.7-month improvement in survival.

Patients who progress on standard sorafenib will undoubtedly benefit from treatment with regorafenib, Abou-Alfa explains.

  <<< View more from the 2017 Chemotherapy Foundation Symposium



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x